Table 4.
Projected drug cost savings resulting from the introduction of Remsima during the first year after launch; combined for switch and naïve patient populations
| Million €a | RA | AS | CD | UC | PsA | Psoriasis | Total |
|---|---|---|---|---|---|---|---|
| 10% discount scenario | |||||||
| Germany | 0.575 | 0.811 | 5.969 | 2.112 | 1.241 | 0.558 | 11.266 |
| UK | 0.597 | 0.190 | 2.118 | 0.327 | 0.185 | 0.205 | 3.621 |
| Italy | 0.646 | 0.677 | 0.734 | 0.932 | 0.967 | 0.670 | 4.625 |
| The Netherlands | 0.257 | 0.235 | 1.784 | 0.967 | 0.101 | 0.044 | 3.389 |
| Belgium | 0.240 | 0.237 | 1.343 | 0.810 | 0.173 | 0.085 | 2.887 |
| Total | 2.315 | 2.150 | 11.949 | 5.148 | 2.667 | 1.561 | 25.789 |
| 20% discount scenario | |||||||
| Germany | 1.149 | 1.623 | 11.939 | 4.225 | 2.481 | 1.117 | 22.532 |
| UK | 1.194 | 0.380 | 4.235 | 0.654 | 0.370 | 0.409 | 7.242 |
| Italy | 1.291 | 1.355 | 1.469 | 1.863 | 1.935 | 1.339 | 9.252 |
| The Netherlands | 0.515 | 0.471 | 3.569 | 1.934 | 0.203 | 0.087 | 6.778 |
| Belgium | 0.480 | 0.474 | 2.686 | 1.621 | 0.345 | 0.169 | 5.775 |
| Total | 4.630 | 4.301 | 23.897 | 10.295 | 5.333 | 3.121 | 51.578 |
| 30% discount scenario | |||||||
| Germany | 1.724 | 2.432 | 17.908 | 6.337 | 3.722 | 1.675 | 33.798 |
| UK | 1.792 | 0.569 | 6.353 | 0.980 | 0.554 | 0.614 | 10.862 |
| Italy | 1.937 | 2.032 | 2.203 | 2.795 | 2.902 | 2.009 | 13.878 |
| The Netherlands | 0.772 | 0.706 | 5.353 | 2.900 | 0.304 | 0.131 | 10.167 |
| Belgium | 0.720 | 0.711 | 4.028 | 2.431 | 0.518 | 0.254 | 8.662 |
| Total | 6.944 | 6.451 | 35.846 | 15.443 | 8.000 | 4.682 | 77.367 |
Numbers have been rounded to the nearest 10,000
AS ankylosing spondylitis, CD Crohn’s disease, PsA psoriatic arthritis, RA rheumatoid arthritis, UC ulcerative colitis
aUK costs were converted to € using a conversion rate of 1.127278 (http://stats.oecd.org/Index.aspx?datasetcode=SNA_TABLE4#)